This Article Full Text Full Text (PDF) All Versions of this Article: 90/7/4394    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Samaras, K. Articles by Cooper, D. A. Search for Related Content PubMed PubMed Citation Articles by Samaras, K. Articles by Cooper, D. A. Related Collections Adrenal and Hypertension Neuroendocrinology and Pituitary Calcium and Bone Metabolism

Iatrogenic Cushing’s Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boosted Protease Inhibitors: Six Cases

Department of Endocrinology (K.S.), St. Vincent’s Hospital and St. Vincent’s Clinic; Immunology and Infectious Diseases Unit (S.P., D.A.C.), St. Vincent’s Hospital; National Centre for HIV Epidemiology and Clinical Research (S.P., D.A.C.), University of New South Wales; and Holdsworth House General Practice (A.G.), Darlinghurst, New South Wales 2010, Australia; and 407 Doctors General Practice (M.M.), Surry Hills, New South Wales 2010, Australia

Address all correspondence and requests for reprints to: Dr. Katherine Samaras, MBBS, FRACP, Ph.D., Diabetes and Obesity Group, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales, 2010, Australia. E-mail: k.samaras{at}garvan.org.au.

Ritonavir, a protease inhibitor (PI), is a potent inhibitor of cytochrome P450 3A4. This pharmacological effect, even at low doses (200 mg/d), is used to "boost" levels of other PIs in the treatment of HIV infection and facilitate once or twice daily dosing with reduced pill burden. Six patients with preexisting HIV-lipodystrophy developed symptomatic Cushing’s syndrome when treated with inhaled fluticasone at varying doses for asthma while concurrently treated with low-dose ritonavir-boosted PI antiretroviral therapy (ART) regimens for HIV infection. There was evidence of adrenal suppression in all patients on stimulation studies. After the withdrawal of inhaled fluticasone, four patients became symptomatic of hypocortisolism, and three required oral corticosteroid support for several months. Other complications included evidence of osteoporosis (n = 3), crush fractures (n = 1), and exacerbation of preexisting type 2 diabetes mellitus (n = 1). In part, the diagnosis of fluticasone-induced Cushing’s syndrome was delayed because all patients had preexisting body composition changes of ART-associated lipodystrophy, masking the Cushing’s features. Practitioners should be aware of the impact on the adrenal axis of coadministration of PI-based ART regimens with inhaled corticosteroids and the potential for exacerbating or even inducing other metabolic conditions, such as osteoporosis or diabetes.

This article has been cited by other articles:

				L. K. Nieman, B. M. K. Biller, J. W. Findling, J. Newell-Price, M. O. Savage, P. M. Stewart, and V. M. Montori The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1526 - 1540. [Abstract] [Full Text] [PDF]

				N. A Bhumbra, E. G Sahloff, S. J Oehrtman, and J. M Horner Exogenous Cushing Syndrome with Inhaled Fluticasone in a Child Receiving Lopinavir/Ritonavir Ann. Pharmacother., July 1, 2007; 41(7): 1306 - 1309. [Abstract] [Full Text] [PDF]

				R. Salvatori Adrenal Insufficiency JAMA, November 16, 2005; 294(19): 2481 - 2488. [Abstract] [Full Text] [PDF]